基因突变的图像。

映像生物 – 源于患者 造福患者 ®

简介 公司新闻 患者创始人

患者创始人

杨瑞

杨瑞先生是一名罕见病患者，患有结晶样视网膜色素变性(Bietti Crystalline Dystrophy (BCD))。BCD是一种罕见的致盲视网膜变性疾病。 BCD影响了杨瑞和他的姐姐，并因此给整个家庭带来巨大负担。因为BCD是罕见病，没有人为BCD开发治疗药物，杨瑞决定以患者身份主动推动医药研发。在失明的过程中，杨瑞和 家人创立了 映像生物有限公司 (映像生物®)，以患者的身份推动BCD基因治疗的研发。 映像生物® 创建并应用 源于患者 造福患者TM 的模式，使患者能够整合资源，积极主动地推动疾病研究和药物开发, 达到利己利他的目的。作为一名由患者转型的研究人员，并通过与我们的研究伙伴合作，杨瑞在失明过程中推动BCD基因治疗的研发，并取得了进展。

杨瑞是国际罕见病研究联盟（IRDiRC）的“孤儿药开发指南”课题组成员，并曾经为专注于罕见病研究的学术期刊《 Orphanet Journal of Rare Diseases》审稿。

杨瑞为 映像生物® 带来了超过15年的法律和金融经验以及在科学领域的背景。在创立 映像生物® 之前，他曾在一家国际投资银行担任董事总经理并专注于医疗领域的投行业务。他的职业生涯始于在纽约从事的律师工作。

杨瑞本科毕业于北京大学化学系，并从密西根大学获得法学博士(J.D.)学位。

发表论文:

1. Yang, R.R. A patient advocating for transparent science in rare disease research. Orphanet J Rare Dis 18, 14 (2023). https://doi.org/10.1186/s13023-022-02557-6

2. Hanany M, Yang RR, Lam CM, Beryozkin A, Sundaresan Y, Sharon D. An in-depth single-gene worldwide carrier frequency and genetic prevalence analysis of CYP4V2 as the cause of Bietti crystalline dystrophy. Transl Vis Sci Technol. 2023;12(2):27,  https://doi.org/10.1167/tvst.12.2.27
An image of DNA signifying the genetic cause.

     ReflectionBio – By Patients, For Patients ®

Introduction Company News Our Patient Founder

Our Patient Founder

Richard Yang

Richard is a rare disease patient suffering from Bietti’s Crystalline Dystrophy (BCD), a late onset retinal degenerative disease. BCD affects Richard and his sister as patients and consequently the entire family’s quality of life. Seeing no one was developing a treatment for BCD, Richard decided to put the matter into his own hands. In the process of going blind, Richard and his family founded Reflection Biotechnologies (ReflectionBio®) to initiate and drive BCD treatment R&D as a patient. ReflectionBio® created and applies the BY PATIENTS, FOR PATIENTS ™ approach for patients to combine efforts and to proactively drive scientific and medical research and development to help ourselves and others. As a patient-turned researcher and in collaboration with our research partners, Richard has been driving BCD gene therapy R&D and made progress in the process of going blind.

Richard is a member of the “Orphan Drug Development Guidebook” Task Force of the International Rare Diseases Research Consortium (IRDiRC). He has served as an ad hoc reviewer for Orphanet Journal of Rare Diseases.

Richard brought to ReflectionBio® more than 15 years of experience in law and finance, and basic training in science. Prior to founding ReflectionBio®, Richard was an Managing Director in healthcare investment banking at a global investment bank. Richard started his career as an attorney in New York.

Richard holds a Juris Doctor (J.D.) degree from The University of Michigan Law School and a Bachelor of Science degree in Chemistry from Peking University.

 Publications:

1. Yang, R.R. A patient advocating for transparent science in rare disease research. Orphanet J Rare Dis 18, 14 (2023).
https://doi.org/10.1186/s13023-022-02557-6

2. Hanany M, Yang RR, Lam CM, Beryozkin A, Sundaresan Y, Sharon D. An in-depth single-gene worldwide carrier frequency and genetic prevalence analysis of CYP4V2 as the cause of Bietti crystalline dystrophy. Transl Vis Sci Technol. 2023;12(2):27,
https://doi.org/10.1167/tvst.12.2.27